Prognostic value of TROP2 in human nasopharyngeal carcinoma |
| |
Authors: | Guo-Fang Guan De-Jun Zhang Lian-Ji Wen Duo-Jiao Yu Yan Zhao Lin Zhu Ying-Yuan Guo Ying Zheng |
| |
Affiliation: | 1.Department of Otolaryngology, Head and Neck Surgery, The Second Hospital of Jilin University, Changchun 130041, P. R. China;2.Department of Otolaryngology, Head and Neck Surgery, Tumor Hospital of Jilin Province, Changchun 130012, P. R. China |
| |
Abstract: | Background: There is increasing evidence demonstrating the role of human trophoblast cell surface antigen 2 (TROP2) in cancer development and progression. However, their prognostic value in Epstein-Barr virus (EBV) associated nasopharyngeal carcinoma (NPC) remains to be elucidated. Method: The prognostic significances of TROP2 and Ki-67 were determined by immunohistochemistry in 58 NPC samples. TROP2 mRNA expression level and biological functions were evaluated. The presence of EBV was assessed using in situ hybridization. Analyses were conducted on the association between each of these variables as well as clinical outcome. Results: TROP2 was exhibited over expression in 64% of NPC samples and significantly associated with highly proliferative tumor cells (P = 0.05) and lymph node metastases (P = 0.03). Overexpression of TROP2 significantly correlated with worse overall survival (P = 0.026) and poor disease-free survival (P = 0.021). By univariate analysis, high expression of TROP2 significantly correlated with patients with distant metastases, Ki-67 and EBV infection. Multivariate analysis further revealed that TROP2 along with Ki-67 and distant metastasis are independent prognostic predictors for NPC patients. Conclusion: Our findings have demonstrated that overexpression of TROP2 appears to be an independent predictor for poor clinical outcome in NPC. The strong correlation of overexpression of TROP2 with Ki-67 and distant metastases indicates a potentially therapeutic strategies targeting TROP2 for NPC patients. |
| |
Keywords: | Nasopharyngeal carcinoma TROP2 EBV prognostic predictor clinical outcome |
|
|